ReviewBritish journal of pharmacology1999
IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.
Review in British journal of pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 69 citations in OpenAlex.
- Overview of the immunomodulatory role of bacterial probiotic-derived peptidoglycan: from molecular insights to therapeutic application.Frontiers in microbiology · 2026Review
- Transcriptomic evidence for atopic dermatitis as a systemic disease in NC/Nga mice.BMC immunology · 2024Article
- The Genetic Landscape of Systemic Rheumatic Diseases: A Comprehensive Multigene-Panel Study Identifying Key Gene Polymorphisms.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- The immune response in canine and human leishmaniasis and how this influences the diagnosis- a review and assessment of recent research.Frontiers in cellular and infection microbiology · 2023Review
- Inosine monophosphate and inosine differentially regulate endotoxemia and bacterial sepsis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Article
- Article
- Anti-Inflammatory and Antinociceptive Studies of Hydroalcoholic Extract from the Leaves ofMolecules (Basel, Switzerland) · 2018Article
- Immunomodulatory Response Triggered by the Alkaloids, 3-Amino-7-Benzylbenzimidazo[3,2-Journal of cancer research and therapeutic oncology · 2015Article
- Oil palm phenolics attenuate changes caused by an atherogenic diet in mice.European journal of nutrition · 2013Article
- Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.Hepatology (Baltimore, Md.) · 2010Article
- Article
- Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever.Rheumatology international · 2007Article
- Gene therapy in the treatment of intestinal inflammation.International journal of colorectal disease · 2004Review
- A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma.Gene therapy · 2003Article
- Article
- Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.British journal of pharmacology · 2001Article
- Receptor-mediated interaction between the sympathetic nervous system and immune system in inflammation.Neurochemical research · 2001Review
- TGF-beta1 null mutation leads to CD154 upregulated expression in affected tissues.Inflammation · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-12 (IL-12) is a pivotal cytokine in driving the immune system towards a T helper (Th)1 type response and preventing a Th2 type immune profile. Therefore, IL-12 is indispensable in the defense against certain, mainly intracellular pathogens, but overproduction of this cytokine is crucially involved in the etiology of several inflammatory and autoimmune diseases. Hence, IL-12 is an ideal target for pharmacological intervention in the therapy of autoimmune and inflammatory diseases. The production of IL-12 and a resultant Th1 type immune response can be suppressed with several pharmacological approaches including modulation of intracellular cyclic AMP levels, glucocorticoids and nuclear factor-kappaB inhibition. IL-12 responsiveness may be inhibited using anti-IL-12 antibodies, soluble IL-12 receptors or the IL-12 p40 homodimer. Exploitation of these approaches may provide novel means for the experimental therapy of a variety of pathophysiological states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.